These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20360041)

  • 1. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.
    Escalas C; Trijau S; Dougados M
    Rheumatology (Oxford); 2010 Jul; 49(7):1317-25. PubMed ID: 20360041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.
    Pham T; Landewé R; van der Linden S; Dougados M; Sieper J; Braun J; Davis J; Rudwaleit M; Collantes E; Burgos-Vargas R; Edmonds J; Olivieri I; van der Horst-Bruinsma I; Mielants H; Stone M; Emery P; van der Heijde D
    Ann Rheum Dis; 2006 Dec; 65(12):1620-5. PubMed ID: 16464984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor inhibitors in ankylosing spondylitis.
    Reed MR; Taylor AL
    Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis.
    Burgos-Vargas R; Rojas-Serrano J
    J Rheumatol; 2005 Sep; 32(9):1637-40. PubMed ID: 16142852
    [No Abstract]   [Full Text] [Related]  

  • 6. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
    Kobelt G
    Rheumatology (Oxford); 2008 Oct; 47(10):1589-90; author reply 1590; discussion 1590-1. PubMed ID: 18710898
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis.
    Marzo-Ortega H; Emery P; McGonagle D
    N Engl J Med; 2003 Jan; 348(4):359-61; author reply 359-61. PubMed ID: 12542065
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.
    Anderson JJ; Baron G; van der Heijde D; Felson DT; Dougados M
    Arthritis Rheum; 2001 Aug; 44(8):1876-86. PubMed ID: 11508441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample sizes estimated in clinical trials using either a composite index (ASAS response criteria) or single outcome variables in ankylosing spondylitis.
    Auleley GR; Dougados M; Baron G
    Arthritis Rheum; 2002 Jun; 46(6):1693-4. PubMed ID: 12115205
    [No Abstract]   [Full Text] [Related]  

  • 13. Can structural damage be prevented in ankylosing spondylitis?
    Sieper J
    Curr Opin Rheumatol; 2009 Jul; 21(4):335-9. PubMed ID: 19424070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ankylosing spondylitis and current disease-controlling agents: do they work?
    Maksymowych WP; Breban M; Braun J
    Best Pract Res Clin Rheumatol; 2002 Sep; 16(4):619-30. PubMed ID: 12406430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?
    Van den Bosch F; De Keyser F; Mielants H; Veys EM
    Arthritis Res Ther; 2005; 7(3):121-3. PubMed ID: 15899063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?
    Wendling D
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):5-7. PubMed ID: 23216081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
    Akkoc N; van der Linden S; Khan MA
    Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):539-57. PubMed ID: 16777581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of ankylosing spondylitis.
    Scalapino KJ; Davis JC
    Clin Exp Med; 2003 Feb; 2(4):159-65. PubMed ID: 12624705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.